131 related articles for article (PubMed ID: 36941759)
1. Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.
Sheng C; Sun L; Lyu Z; Li L; Zhang Y; Zhang Y; Zhang Y; Dai H; Huang Y; Song F; Yuan Y; Chen K
Helicobacter; 2023 Jun; 28(3):e12966. PubMed ID: 36941759
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for
Wang SS; Guo ZP; Zhao XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 54(1):186-191. PubMed ID: 36647665
[TBL] [Abstract][Full Text] [Related]
3. Role of Serum Pepsinogen II and
Baek SM; Kim N; Kwon YJ; Lee HS; Kim HY; Lee J; Yoon H; Shin CM; Park YS; Lee DH
Gut Liver; 2020 Jul; 14(4):439-449. PubMed ID: 31533397
[TBL] [Abstract][Full Text] [Related]
4. Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study.
Chinda D; Shimoyama T; Mikami T; Arai T; Chiba D; Sasaki Y; Komai K; Sawada Y; Saito Y; Chiba H; Fukuda S;
J Gastroenterol; 2018 Aug; 53(8):924-931. PubMed ID: 29353347
[TBL] [Abstract][Full Text] [Related]
5. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
6. Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.
Hamashima C; Sasazuki S; Inoue M; Tsugane S;
BMC Cancer; 2017 Mar; 17(1):183. PubMed ID: 28279154
[TBL] [Abstract][Full Text] [Related]
7. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method.
Yamaguchi Y; Nagata Y; Hiratsuka R; Kawase Y; Tominaga T; Takeuchi S; Sakagami S; Ishida S
Digestion; 2016; 93(1):13-8. PubMed ID: 26789514
[TBL] [Abstract][Full Text] [Related]
8. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".
Miki K
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(7):405-14. PubMed ID: 21785258
[TBL] [Abstract][Full Text] [Related]
9. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the GastroPanel test and the serum pepsinogen assay interpreted with the ABC method-A prospective study.
Lee SY; Ahn YS; Moon HW
Helicobacter; 2024; 29(1):e13056. PubMed ID: 38402559
[TBL] [Abstract][Full Text] [Related]
11.
MÄki M; SÖderstrÖm D; Paloheimo L; Hendolin P; Suovaniemi O; SyrjÄnen K
Anticancer Res; 2020 Nov; 40(11):6387-6398. PubMed ID: 33109577
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of different serological methods in screening early gastric cancer].
Ni DQ; Lyu B; Bao HB; Jin HF; Zhao J; Xu Y; Huang X
Zhonghua Nei Ke Za Zhi; 2019 Apr; 58(4):294-300. PubMed ID: 30917423
[No Abstract] [Full Text] [Related]
13. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel®) in St. Petersburg.
Roman LD; Lukyanchuk R; Sablin OA; Araslanova EI; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
Anticancer Res; 2016 Aug; 36(8):4129-38. PubMed ID: 27466521
[TBL] [Abstract][Full Text] [Related]
15. Follow-up study on a high risk population of gastric cancer in north China by serum pepsinogen assay.
Sun LP; Gong YH; Wang L; Gong W; Yuan Y
J Dig Dis; 2008 Feb; 9(1):20-6. PubMed ID: 18251790
[TBL] [Abstract][Full Text] [Related]
16. Identification of Helicobacter pylori-related gastric cancer risk using serological gastritis markers and endoscopic findings: a large-scale retrospective cohort study.
Nagasaki N; Ito M; Boda T; Kotachi T; Takigawa H; Oka S; Tanaka S
BMC Gastroenterol; 2022 Jun; 22(1):299. PubMed ID: 35725370
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
18. Serum pepsinogen cut-off values in Helicobacter pylori-infected children.
Fujiwara SI; Konno M; Watanabe S; Toita N; Takahashi M
Pediatr Int; 2022 Jan; 64(1):e15247. PubMed ID: 36257610
[TBL] [Abstract][Full Text] [Related]
19. Type I and type II
Yuan L; Zhao JB; Zhou YL; Qi YB; Guo QY; Zhang HH; Khan MN; Lan L; Jia CH; Zhang YR; Ding SZ
World J Gastroenterol; 2020 Jul; 26(25):3673-3685. PubMed ID: 32742135
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
